Summary

This is a single-center, open-label, non-randomized safety and efficacy trial to evaluate co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from the same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression. 

A total of 8 patients will be enrolled in the study and followed for a minimum of 1 year up to 2 years after the last islet transplantation, depending on enrollment. The islet manufacturing protocol and patient treatment and monitoring procedures are based on those used in the NIH CIT 06 trial.

Sponsor

California Institute of Regenerative Medicine (CIRM) 

Status of enrollment

Open to accrual

Ages Eligible for Study

18 years and older

Genders Eligible for Study

Males and Females

Disease indication

Type 1 diabetes (onset <40 years old and insulin dependent for > 5 years at enrollment, c-peptide negative).

Principal Investigator

Peter Stock, MD

Contact

Rodney Rogers: [email protected] 

Additional study eligibility details can be found at UCSF Clinical Trials.